Final overall survival (OS) analysis of PROfound: Olaparib vs physician's choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

de Bono J. S., Mateo J., Fizazi K., Saad F., Shore N., Sandhu S., ...More

ESMO Virtual Congress, ELECTR NETWORK, 19 September - 18 October 2020, vol.31, (Summary Text)

  • Publication Type: Conference Paper / Summary Text
  • Volume: 31
  • Doi Number: 10.1016/j.annonc.2020.08.870
  • Country: ELECTR NETWORK
  • Istanbul University Affiliated: No